Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

BACKGROUND: The modest benefits of gemcitabine (dFdC) therapy in patients with pancreatic ductal adenocarcinoma (PDAC) are well documented, with drug delivery and metabolic lability cited as important contributing factors. We have used a mouse model of PDAC: KRAS(G12D); p53(R172H); pdx-Cre (KPC) tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bapiro, T E, Frese, K K, Courtin, A, Bramhall, J L, Madhu, B, Cook, N, Neesse, A, Griffiths, J R, Tuveson, D A, Jodrell, D I, Richards, F M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102943/
https://www.ncbi.nlm.nih.gov/pubmed/24874484
http://dx.doi.org/10.1038/bjc.2014.288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102943/
https://www.ncbi.nlm.nih.gov/pubmed/24874484
http://dx.doi.org/10.1038/bjc.2014.288

Ejemplares similares